
Expert Support from First Run to Full Scale
Whether you’re launching your AAV process or ready to scale, we’re here to help set your therapy up for manufacturing success.
Your Collaborative Partner from Idea to Impact
We know that no two gene therapy programs are alike, which is why biotech companies need a manufacturing collaborator with deep expertise across serotypes, indications, and scales—and solutions for every stage of your program.
Fuel Your Process Development with Forge’s Robust Platform
Our FUEL™ platform offers a powerful head start with an innovative AAV manufacturing foundation built to help biotech companies scale efficiently.
Analytics to Prepare Your Program for cGMP
We offer over 25 in-house assays for efficient and accelerated characterization and release, including NGS, potency, and rcAAV.
Scale and Support for cGMP
Our process development and cGMP scale-up and scale-down capabilities support a commercial suspension platform. From technology transfer to fill-finish—Forge has you covered.

a partner for growth
We Help Scale Your Gene Therapies
With numerous development studies, scales, and AAV grades available to shape manufacturing pathways and reach key milestones, a common two-fold question we hear from biotech developers is: “Where do I start, and will it work?” We help navigate these decisions and scale programs with confidence — from selecting the right approach and leveraging our FUEL™ platform to optimizing for yield and driving toward commercial success.

innovation
Innovation that Powers Your Progress
Biotech companies need a manufacturing partner that is relentlessly innovating to help them stay ahead. Our investments in manufacturing R&D have led to real advantages for developers through novel technologies in our FUEL™ platform, including our HEK293 suspension Ignition Cells™, pEMBR™ 2.0 Ad helper plasmid, and modified rep/cap plasmids. Everything is designed to help you develop, manufacture and deliver transformative therapies faster, safer, and to more patients.

Designed to scale with you
State-of-the-Art cGMP CDMO Facility
Our facility offers cutting-edge technologies and ample capacity to scale as your program advances, with 20 cGMP suites and bioreactors ranging from 50 to 5,000L. We’re ready to support you from your first run through to full scale production.

guidance
Expert Regulatory Guidance for Biotechs
Navigating regulatory requirements can be complex and time-consuming for biotech companies advancing new therapies. Forge provides the guidance and support you need, from DMF cross-referencing and Module 3 guide to tailored consulting, documentation support, and strategic input to help streamline IND filings and strengthen your regulatory strategy across every stage of development.

Forge Your Path
Let’s talk about how we can bring your AAV program to scale today.
Hot off the Forge
-
Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Forge’s presentations at the Meeting of the American Society of Gene and Cell Therapy highlight cell line and plasmid developments.
-
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
Through this partnership, Forge will help Life Bio advance their innovative cellular rejuvenation technology.
-
Oculogenex and Forge Biologics Announce AAV Contract Development and Manufacturing Partnership
Forge will provide services to support Oculogenex’ gene therapy program for patients with dry age-related macular degeneration (AMD) toward clinical trials.
-
Forge Biologics Announces Seven Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Five scientific poster presentations highlight scalable process and analytical developments for AAV manufacturing.